Provided by Tiger Trade Technology Pte. Ltd.

Agilent

159.00
+2.701.73%
Post-market: 158.96-0.0363-0.02%19:50 EDT
Volume:2.73M
Turnover:433.91M
Market Cap:45.01B
PE:31.93
High:160.51
Open:156.50
Low:155.24
Close:156.30
52wk High:160.51
52wk Low:108.35
Shares:283.05M
Float Shares:281.64M
Volume Ratio:1.43
T/O Rate:0.97%
Dividend:1.01
Dividend Rate:0.63%
EPS(TTM):4.98
EPS(LYR):4.59
ROE:21.33%
ROA:8.61%
PB:6.32
PE(LYR):34.66

Loading ...

Agilent Technologies Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Jun 10

Revvity Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jun 09

Agilent Technologies Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Jun 09

Agilent files Form 3 for VP, Chief Accounting Officer Timothy Charles Downs

Reuters
·
Jun 06

A Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus

Simply Wall St.
·
Jun 05

Revvity Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Jun 05

Agilent Technologies Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jun 04

Agilent Technologies Partners With OpenAI, Boston Consulting for AI Deployment

MT Newswires Live
·
Jun 03

Agilent teams with OpenAI, BCG to scale AI across products and operations

Reuters
·
Jun 03

Agilent, OpenAI, Bcg Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

THOMSON REUTERS
·
Jun 03

Agilent price target lowered to $165 from $180 at HSBC

TIPRANKS
·
Jun 03

U.S. RESEARCH ROUNDUP-Aveanna Healthcare, Palo Alto, Ulta Beauty

Reuters
·
Jun 03

Agilent receives FDA approval for expanded use of PD-L1 IHC 22C3 pharmDx

TIPRANKS
·
Jun 03

Agilent Technologies' Cancer Test Gets Expanded Approval From FDA

Dow Jones
·
Jun 03

Agilent wins FDA nod to expand PD-L1 22C3 test use on Dako Omnis platform

Reuters
·
Jun 03

Agilent Receives FDA Approval for Expanded Use of Pd-L1 Ihc 22C3 Pharmdx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

THOMSON REUTERS
·
Jun 03

Agilent director Mikael Dolsten sells 1,600 common shares for $216,672

Reuters
·
Jun 03

Agilent Is Maintained at Buy by B of A Securities

Dow Jones
·
Jun 03

BofA Securities Adjusts Agilent Technologies PT to $155 From $145

MT Newswires Live
·
Jun 02

Triller Group Inc. Receives Nasdaq Exception To Regain Minimum Bid Price Compliance

GlobeNewswire
·
Jun 02